New and emerging therapies for sepsis

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 648-654

  Healy, Daniel P ^a   Monsanto, Homero A ^a   Dion, Pierre ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Activated protein C; Afelimomab; Antithrombin III; Drotrecogin alfa; Platelet activating factor acetylhydrolase; Pydridoxylated hemoglobin polyoxyethylene; Sepsis; Tifacogin; Tissue factor pathway inhibitor; Tumor necrosis factor antibody

Indexed keywords

ACTIVATED PROTEIN C; AFELIMOMAB; ANTITHROMBIN III; DROTRECOGIN; MONOCLONAL ANTIBODY; PYRIDOXYLPOLYHEMOGLOBIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ACETLYHYDROLASE; THROMBOCYTE ACTIVATING FACTOR DERIVATIVE; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; FIBRINOLYSIS; HUMAN; INFLAMMATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MULTIPLE ORGAN FAILURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS;

EID: 0036205471     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A283     Document Type: Review

References (34)

1. The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error
2. Treating patients with severe sepsis
3. Why sepsis trials fail
4. Adjunctive therapy for septic shock: A review of experimental approaches
5. Time course of hemostatic abnormalities in sepsis and its relation to outcome
6. The role of the endothelium in changes in procoagulant activity in sepsis
7. Alterations in coagulation and fibrinolysis during sepsis
8. Inflammation and thrombosis. Mutual regulation by protein C
9. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome
10. Pathogenic mechanisms of septic shock
11. Activation of coagulation after administration of tumor necrosis factor to normal subjects
12. Vascular-bed-specific hemostasis and hypercoagulable states
13. Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis
14. Has the mortality of septic shock changed with time?
15. Epidemiology of sepsis: An update
16. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
17. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis
18. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
19. Disseminated intravascular coagulation
20. The endothelium in sepsis: Source of and a target for inflammation
21. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
22. Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C
23. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation
24. Efficacy and safety of recombinant human activated protein C for severe sepsis
25. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis
26. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
27. Anti-tumor necrosis factor therapy in sepsis: An update on clinical trials and lessons learned
28. Cytokine serium level during severe sepsis in human IL-6 as a marker of severity
29. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study
30. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial
31. Anti-tumor necrosis factor therapy for sepsis: Still a player?
32. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
33. High-dose antithrombin III in severe sepsis. A randomized controlled trial